To ensure the reliability of our findings and avoid masking potential benefits on Hb levels, we specifically targeted patients with stable PTH levels corresponding to their CKD stage, maintaining a balanced calcium-phosphate ratio without any signs of inflammation. This evidence concerns the gene GSTM1 and chronic kidney disease.